Article

China's National Medical Products Administration has suspended the import, sale, and use of Sun Pharma's rivastigmine hydrogen tartrate capsules due to deficiencies in production quality management and contamination prevention identified during a remote inspection. The findings highlighted inadequacies in the quality management team's risk assessment capabilities, following a history of regulatory issues for Sun Pharma's manufacturing site in India. Additionally, NMPA has banned Supriya Lifescience's chlorpheniramine maleate raw material for similar management deficiencies.